Alnylam partners with Inceptive in $2B AI collaboration for drug discovery
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics
June 3, 2026 4:45 PM EDTCollaboration is valued at up to $2B with upfront consideration of $30M
Alliance pairs Alnylams RNAi platform and 20+ years of proprietary data with Inceptives foundation models and AI expertise to catalyze progress beyond rational drug design
Partnership designed to accelerate timelines and unlock innovative oligonucleotide designs
CAMBRIDGE, Mass. & PALO ALTO, Calif.--(BUSINESS WIRE)-- Alnylam... More
